Applied Biosystems, a division of Life Technologies Corporation (NASDAQ:LIFE), today announced a set of new services offered through its Global Services organization to better support its mass spectrometry customers. The new services include: compliance services for regulated laboratories to simplify and facilitate deployment of SCIEX 5500 systems; an expanded Web-based solution for remote monitoring of the latest Applied Biosystems/MDS Analytical Technologies mass spectrometry systems; and a new maintenance program for high-performance liquid chromatography (HPLC) systems and auto-samplers, manufactured by Shimadzu Corporation. These specialized services support complete workflows to help laboratories maintain compliance, maximize productivity and better manage integration.
Applied Biosystems is offering these value-added services in response to customer demand to have a single provider of complete workflow solutions for mass spectrometry technologies. These services include:
- End-to-end Shimadzu HPLC/SCIEX Mass Spectrometer Maintenance Service - Applied Biosystems Global Services will provide service and support for Shimadzu HPLC instruments and serve as a single point of contact for joint solutions. HPLC instruments are often combined with mass spectrometers to form a complete workflow solution for separating, identifying and quantifying compounds for analysis in high-throughput applications, such as drug discovery.
- Compliance Services for SCIEX 5500 Systems - Applied Biosystems is expanding its suite of Compliance Services to simplify and reduce customers' costs associated with the validation of SCIEX 5500 Systems to support regulated drug-development applications.
- Smart Services Remote Instrument Monitoring - The SCIEX 5500 Systems are now supported by Applied Biosystems Smart Monitoring Service, which provides real-time remote instrument monitoring and diagnostics that help laboratories maximize system uptime, better manage their labs and improve overall productivity
Mark O'Donnell, Senior Vice President of Global Operations and Services at Life Technologies
"Mass spectrometry users are seeking a single point of support and accountability for a complete workflow-based system. Applied Biosystems Global Services is delivering on its commitment to support end-to-end solutions and helping customers migrate smoothly to new innovations, such as the SCIEX 5500 Systems and Cliquid® MPXTM high-throughput solution, in compliance with regulatory requirements and industry standards."
Overview of the Global Services organization
About Applied Biosystems Products
Applied Biosystems is a global leader in providing innovative instrument systems to accelerate academic and clinical research, drug discovery and development, pathogen detection and forensic DNA analysis. Applied Biosystems, along with Invitrogen - a leading provider of platform independent, essential life science technologies for disease and drug research, bioproduction and diagnostics - is part of Life Technologies. Applied Biosystems and Invitrogen products are used in nearly every major laboratory in the world.
About Life Technologies
Life Technologies Corporation (NASDAQ:LIFE) is a global biotechnology tools company dedicated to improving the human condition. Our systems, consumables and services enable researchers to accelerate scientific exploration, driving to discoveries and developments that make life even better. Life Technologies customers do their work across the biological spectrum, working to advance personalized medicine, regenerative science, molecular diagnostics, agricultural and environmental research, and 21st century forensics. Life Technologies had sales of more than $3 billion in 2008, employs approximately 9,500 people, has a presence in more than 100 countries, and possesses a rapidly growing intellectual property estate of approximately 3,600 patents and exclusive licenses. Life Technologies was created by the combination of Invitrogen Corporation and Applied Biosystems Inc.
Safe Harbor Statement
This press release includes forward-looking statements about our anticipated results that involve risks and uncertainties. Some of the information contained in this press release, including, but not limited to, statements as to industry trends and Life Technologies' plans, objectives, expectations and strategy for its business, contains forward-looking statements that are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Any statements that are not statements of historical fact are forward-looking statements. When used, the words "believe," "plan," "intend," "anticipate," "target," "estimate," "expect" and the like, and/or future tense or conditional constructions ("will," "may," "could," "should," etc.), or similar expressions, identify certain of these forward-looking statements. Important factors which could cause actual results to differ materially from those in the forward-looking statements are detailed in filings made by Life Technologies with the Securities and Exchange Commission. Life Technologies undertakes no obligation to update or revise any such forward-looking statements to reflect subsequent events or circumstances.